CL
Insider
Casdin Capital, LLC
DirectorCasdin Capital, LLC (Director) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in GeneDx Holdings Corp. (WGS). Across 2 priced purchase filings, the average 21-session return was +36.2% from execution and +32.5% from disclosure (delay-adjusted; derived). The largest single filing was $21.5M of WGS (500,000 sh across 3 lots, as filed), executed May 18.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+36.2%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+32.5%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$32.6M
shares × price, as filed
Last traded
Jun 5
Filed Jun 8
Median ADV $82.7M across their filed names
Open performance→Volume by month
Buys $37.7M
Sells $12.2M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
WGSRecent filings
WGSPURCHASE
GeneDx Holdings Corp.
View filing →
$11.1M200,000 sh across 2 lots
Exec Jun 4
Filed Jun 8 · 5:25 PM ET WGSPURCHASE GeneDx Holdings Corp. View filing → $21.5M
500,000 sh across 3 lots
Exec May 18
Filed May 20 · 7:45 PM ET BLFSSALE BIOLIFE SOLUTIONS INC View filing → $12.2M
500,000 sh × $24.40
Exec Aug 15 2025
Filed Aug 21 2025 · 5:30 PM ET † LABPURCHASE STANDARD BIOTOOLS INC. View filing → $5.2M
4,820,959 sh × $1.07
Exec Feb 28 2025
Filed Mar 4 2025 · 5:30 PM ET